Hyloris remains on-track to broaden its product pipeline to its target of 30 product candidates and marketed products by 2024, delivering a confident-half year update in the face of some pushback from the US Food and Drug Administration.
The firm remains closely focused on two marketed and commercial-stage programs: Sotalol IV, an atrial fibrillation treatment, and Maxigesic IV...